NASH-Liver disease affects 2-5% of Americans -Reason for Epadel phase 2 trials.
Vascepa some day--could be used for Liver disease--NASH-- if Epadel's Phase 2 trials are significant.
Currently no drug has been identified if you read National Digestive Disease Information on Steato-Hepatitis.
POTENTIAL SALES is HUGE.
I do not think Amarin knows.
Mochida which sold Epadel(90% pure EPA) in Japan is trying to extend Epadel use in other big area.There are 7-20 million who suffer from this Liver disease-silently.
It will be interesting to watch phase 2 trials for Epadel in Japan.